242 related articles for article (PubMed ID: 38040069)
1. BDE-47 induces metabolic dysfunction-associated steatotic liver disease (MASLD) through CD36-mediated increased fatty acid uptake and PPARα-induced abnormal fatty acid oxidation in BALB/c mice.
Xia B; Yu R; Liu J; Liu D; Li S; Yang L; Liu N; Liang B; Zeng J; Wei J; Lin G
Toxicol Lett; 2024 Jan; 391():100-110. PubMed ID: 38040069
[TBL] [Abstract][Full Text] [Related]
2. A novel role for the dioxin receptor in fatty acid metabolism and hepatic steatosis.
Lee JH; Wada T; Febbraio M; He J; Matsubara T; Lee MJ; Gonzalez FJ; Xie W
Gastroenterology; 2010 Aug; 139(2):653-63. PubMed ID: 20303349
[TBL] [Abstract][Full Text] [Related]
3. The ubiquitin-like modifier FAT10 is induced in MASLD and impairs the lipid-regulatory activity of PPARα.
Clavreul L; Bernard L; Cotte AK; Hennuyer N; Bourouh C; Devos C; Helleboid A; Haas JT; Verrijken A; Gheeraert C; Derudas B; Guille L; Chevalier J; Eeckhoute J; Vallez E; Dorchies E; Van Gaal L; Lassailly G; Francque S; Staels B; Paumelle R
Metabolism; 2024 Feb; 151():155720. PubMed ID: 37926201
[TBL] [Abstract][Full Text] [Related]
4. Linalool attenuates lipid accumulation and oxidative stress in metabolic dysfunction-associated steatotic liver disease via Sirt1/Akt/PPRA-α/AMPK and Nrf-2/HO-1 signaling pathways.
Tamilmani P; Sathibabu Uddandrao VV; Chandrasekaran P; Saravanan G; Brahma Naidu P; Sengottuvelu S; Vadivukkarasi S
Clin Res Hepatol Gastroenterol; 2023 Dec; 47(10):102231. PubMed ID: 37865226
[TBL] [Abstract][Full Text] [Related]
5. Dietary α-lactalbumin induced fatty liver by enhancing nuclear liver X receptor αβ/sterol regulatory element-binding protein-1c/PPARγ expression and minimising PPARα/carnitine palmitoyltransferase-1 expression and AMP-activated protein kinase α phosphorylation associated with atherogenic dyslipidaemia, insulin resistance and oxidative stress in Balb/c mice.
López-Oliva ME; Garcimartin A; Muñoz-Martínez E
Br J Nutr; 2017 Dec; 118(11):914-929. PubMed ID: 29173234
[TBL] [Abstract][Full Text] [Related]
6. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments.
Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895151
[TBL] [Abstract][Full Text] [Related]
7. Effects of apolipoprotein H downregulation on lipid metabolism, fatty liver disease, and gut microbiota dysbiosis.
Liu Y; Zhao Y; Liu Q; Li B; Daniel PV; Chen B; Wu Z
J Lipid Res; 2024 Jan; 65(1):100483. PubMed ID: 38101620
[TBL] [Abstract][Full Text] [Related]
8. Perfluoroalkyl acids-induced liver steatosis: Effects on genes controlling lipid homeostasis.
Das KP; Wood CR; Lin MT; Starkov AA; Lau C; Wallace KB; Corton JC; Abbott BD
Toxicology; 2017 Mar; 378():37-52. PubMed ID: 28049043
[TBL] [Abstract][Full Text] [Related]
9. Farnesol induces fatty acid oxidation and decreases triglyceride accumulation in steatotic HepaRG cells.
Pant A; Rondini EA; Kocarek TA
Toxicol Appl Pharmacol; 2019 Feb; 365():61-70. PubMed ID: 30611723
[TBL] [Abstract][Full Text] [Related]
10. Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) via modulation of PPARα and SREBP-1.
Ziamajidi N; Khaghani S; Hassanzadeh G; Vardasbi S; Ahmadian S; Nowrouzi A; Ghaffari SM; Abdirad A
Food Chem Toxicol; 2013 Aug; 58():198-209. PubMed ID: 23603006
[TBL] [Abstract][Full Text] [Related]
11. Co-option of PPARα in the regulation of lipogenesis and fatty acid oxidation in CLA-induced hepatic steatosis.
Cai D; Li Y; Zhang K; Zhou B; Guo F; Holm L; Liu HY
J Cell Physiol; 2021 Jun; 236(6):4387-4402. PubMed ID: 33184849
[TBL] [Abstract][Full Text] [Related]
12. Chronic exposure to tetrabromodiphenyl ether (BDE-47) aggravates hepatic steatosis and liver fibrosis in diet-induced obese mice.
Yang C; Zhu L; Kang Q; Lee HK; Li D; Chung ACK; Cai Z
J Hazard Mater; 2019 Oct; 378():120766. PubMed ID: 31226595
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic role of ursolic acid on ameliorating hepatic steatosis and improving metabolic disorders in high-fat diet-induced non-alcoholic fatty liver disease rats.
Li S; Liao X; Meng F; Wang Y; Sun Z; Guo F; Li X; Meng M; Li Y; Sun C
PLoS One; 2014; 9(1):e86724. PubMed ID: 24489777
[TBL] [Abstract][Full Text] [Related]
14. NIK links inflammation to hepatic steatosis by suppressing PPARα in alcoholic liver disease.
Li Y; Chen M; Zhou Y; Tang C; Zhang W; Zhong Y; Chen Y; Zhou H; Sheng L
Theranostics; 2020; 10(8):3579-3593. PubMed ID: 32206109
[No Abstract] [Full Text] [Related]
15. Lipidomic Analysis Reveals Alterations in Hepatic FA Profile Associated With MASLD Stage in Patients With Obesity.
Núñez-Sánchez MÁ; Martínez-Sánchez MA; Martínez-Montoro JI; Balaguer-Román A; Murcia-García E; Fernández-Ruiz VE; Ferrer-Gómez M; Martínez-Cáceres CM; Sledzinski T; Frutos MD; Hernández-Morante JJ; Fernández-García JC; Queipo-Ortuño MI; Ruiz-Alcaraz AJ; Mika A; Ramos-Molina B
J Clin Endocrinol Metab; 2024 Jun; 109(7):1781-1792. PubMed ID: 38217869
[TBL] [Abstract][Full Text] [Related]
16. Metabolomics and lipidomics study unveils the impact of polybrominated diphenyl ether-47 on breast cancer mice.
Wei J; Li X; Xiang L; Song Y; Liu Y; Jiang Y; Cai Z
J Hazard Mater; 2020 May; 390():121451. PubMed ID: 31796364
[TBL] [Abstract][Full Text] [Related]
17. Ferulic Acid Prevents Nonalcoholic Fatty Liver Disease by Promoting Fatty Acid Oxidation and Energy Expenditure in C57BL/6 Mice Fed a High-Fat Diet.
Luo Z; Li M; Yang Q; Zhang Y; Liu F; Gong L; Han L; Wang M
Nutrients; 2022 Jun; 14(12):. PubMed ID: 35745260
[TBL] [Abstract][Full Text] [Related]
18. Steatogenesis in adult-onset type II citrullinemia is associated with down-regulation of PPARα.
Komatsu M; Kimura T; Yazaki M; Tanaka N; Yang Y; Nakajima T; Horiuchi A; Fang ZZ; Joshita S; Matsumoto A; Umemura T; Tanaka E; Gonzalez FJ; Ikeda S; Aoyama T
Biochim Biophys Acta; 2015 Mar; 1852(3):473-81. PubMed ID: 25533124
[TBL] [Abstract][Full Text] [Related]
19. Isosilybin regulates lipogenesis and fatty acid oxidation via the AMPK/SREBP-1c/PPARα pathway.
Liu X; Hu M; Ye C; Liao L; Ding C; Sun L; Liang J; Chen Y
Chem Biol Interact; 2022 Dec; 368():110250. PubMed ID: 36347319
[TBL] [Abstract][Full Text] [Related]
20. Diosgenin attenuates nonalcoholic hepatic steatosis through the hepatic FXR-SHP-SREBP1C/PPARα/CD36 pathway.
Chen S; Sun S; Feng Y; Li X; Yin G; Liang P; Yu W; Meng D; Zhang X; Liu H; Zhang F
Eur J Pharmacol; 2023 Aug; 952():175808. PubMed ID: 37263401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
